Summary of the PC-BETS Substudy C: Darolutamide in Biomarker-Selected mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxEarly Results of Gedatolisib and Darolutamide in mCRPC Treatment
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1/2 For a New PARP1 Inhibitor: EIK1004 (IMP1707) For mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1/2 Trial: MT-4561 Targeting BRD4 in Metastatic Prostate Cancer and Neuroendocrine Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxNEPC
Phase 2 Trial: ZG006 a New Immunotherapy for Neuroendocrine Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1/2 Trial: Targeting Resistance With SX-682 And Apalutamide or Enzalutamide
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxSn-117m-DTPA Emerges as Theranostic: Phase 1/2 Trials
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 2 Clinical Trial: JSB462 (Luxdegalutamide) in Combination With Abiraterone for mHSPC
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1/2 Clinical Trial: 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Phase 1: SYN608 Targets DNA Repair in HRR-Deficient Prostate and Other Solid Tumors July 30, 2025
- Phase 1 Trial of a Triple Combination: 177Lu-PSMA-I&T, Olaparib, and Pembrolizumab July 30, 2025
- LYA914: A Novel Oral PROTAC Targeting Androgen Receptor Variants in Prostate Cancer July 30, 2025
- Phase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond July 29, 2025